Source: Circulation. Conference titles: Scientific Sessions of the American Heart Association. Unidade: FM
Subjects: ADJUVANTES IMUNOLÓGICOS, FATORES DE RISCO, CORONARIOPATIA (IMUNOLOGIA)
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
FERNANDES, Juliano L. et al. Immunomodulating agent pentoxifylline reduces the inflammatory activity in patient with high-risk non-ST-segment elevation acute coronary syndromes: results of the randomized, double-blind, placebo-controlled, reduction of cardiac adverse events acute coronary syndromes with pentoxifylline (RECAP) pilot trial. Circulation. Philadelphia: Faculdade de Medicina, Universidade de São Paulo. . Acesso em: 05 set. 2024. , 2004APA
Fernandes, J. L., Oliveira, R. T., Mamoni, R. L., Nicolau, J. C., Coelho, O. R., Blotta, M. H. S., & Serrano Junior, C. V. (2004). Immunomodulating agent pentoxifylline reduces the inflammatory activity in patient with high-risk non-ST-segment elevation acute coronary syndromes: results of the randomized, double-blind, placebo-controlled, reduction of cardiac adverse events acute coronary syndromes with pentoxifylline (RECAP) pilot trial. Circulation. Philadelphia: Faculdade de Medicina, Universidade de São Paulo.NLM
Fernandes JL, Oliveira RT, Mamoni RL, Nicolau JC, Coelho OR, Blotta MHS, Serrano Junior CV. Immunomodulating agent pentoxifylline reduces the inflammatory activity in patient with high-risk non-ST-segment elevation acute coronary syndromes: results of the randomized, double-blind, placebo-controlled, reduction of cardiac adverse events acute coronary syndromes with pentoxifylline (RECAP) pilot trial. Circulation. 2004 ; 110( 17): 449.[citado 2024 set. 05 ]Vancouver
Fernandes JL, Oliveira RT, Mamoni RL, Nicolau JC, Coelho OR, Blotta MHS, Serrano Junior CV. Immunomodulating agent pentoxifylline reduces the inflammatory activity in patient with high-risk non-ST-segment elevation acute coronary syndromes: results of the randomized, double-blind, placebo-controlled, reduction of cardiac adverse events acute coronary syndromes with pentoxifylline (RECAP) pilot trial. Circulation. 2004 ; 110( 17): 449.[citado 2024 set. 05 ]